Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib

MELBOURNE, Australia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today highlighted new preclinical data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC) and compared that profile with a clinical standard recently established by Revolution Medicines, Inc.

On August 26, 2026, the U.S. Food and Drug Administration approved daraxonrasib (RASONQUE), Revolution Medicines’ oral RAS(ON) multi-selective inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multiagent systemic therapy. Approval was based on the Phase 3 RASolute 302 trial. In the RAS G12 population, daraxonrasib delivered median overall survival of 13.2 months versus 6.6 months with chemotherapy (hazard ratio 0.40), median progression-free survival of 7.3 months versus 3.5 months (hazard ratio 0.45), and a confirmed objective response rate of 33.2% versus 11.8%. Results in the intent-to-treat population were consistent: median overall survival 13.2 versus 6.7 months (hazard ratio 0.40) and median progression-free survival 7.2 versus 3.6 months (hazard ratio 0.49).